메뉴 건너뛰기




Volumn 51, Issue 25, 2008, Pages 2375-2384

Managing Dyslipidemia in Chronic Kidney Disease

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

EID: 44949180810     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.03.025     Document Type: Review
Times cited : (178)

References (54)
  • 1
    • 80052585091 scopus 로고    scopus 로고
    • National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health Accessed July 6, 2007
    • National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. U.S. Renal Data System: USRDS 2000 annual report, Bethesda, Maryland. http://www.usrds.org/atlas_2000.htm Accessed July 6, 2007
    • U.S. Renal Data System: USRDS 2000 annual report, Bethesda, Maryland
  • 2
    • 44949169590 scopus 로고    scopus 로고
    • U.S. Renal Data System, Division of Kidney, Urologic, and Hematological Disease, National Institute of Diabetes and Digestive Disease, National Institutes of Health, Bethesda, MD
    • U.S. Renal Data System. USRDS 2000 annual data report: atlas of endstage renal diseases in the United States (12th annual report) (2000), Division of Kidney, Urologic, and Hematological Disease, National Institute of Diabetes and Digestive Disease, National Institutes of Health, Bethesda, MD
    • (2000) USRDS 2000 annual data report: atlas of endstage renal diseases in the United States (12th annual report)
  • 3
    • 0024370790 scopus 로고
    • Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program
    • Hypertension Detection and Follow-Up Program Cooperative Group
    • Shulman N.B., Ford C.E., Hall W.D., et al., Hypertension Detection and Follow-Up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 13 (1989) I80-I93
    • (1989) Hypertension , vol.13
    • Shulman, N.B.1    Ford, C.E.2    Hall, W.D.3
  • 4
    • 33644854296 scopus 로고    scopus 로고
    • Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences
    • Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol 290 (2005) F262-F272
    • (2005) Am J Physiol Ren Physiol , vol.290
    • Vaziri, N.D.1
  • 5
    • 0242441465 scopus 로고    scopus 로고
    • Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
    • Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
    • (2003) Hypertension , vol.42 , pp. 1050-1065
    • Sarnak, M.J.1    Levey, A.S.2    Schoolwerth, A.C.3
  • 7
    • 0037394435 scopus 로고    scopus 로고
    • Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals
    • Fried L.F., Shlipak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1364-1372
    • Fried, L.F.1    Shlipak, M.G.2    Crump, C.3
  • 8
    • 20544467918 scopus 로고    scopus 로고
    • Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999
    • Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005) 489-495
    • (2005) J Am Soc Nephrol , vol.16 , pp. 489-495
    • Foley, R.N.1    Murray, A.M.2    Li, S.3
  • 9
    • 16844376116 scopus 로고    scopus 로고
    • Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study
    • Muntner P., He J., Astor B.C., Folsom A.R., and Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16 (2005) 529-538
    • (2005) J Am Soc Nephrol , vol.16 , pp. 529-538
    • Muntner, P.1    He, J.2    Astor, B.C.3    Folsom, A.R.4    Coresh, J.5
  • 10
    • 0034805996 scopus 로고    scopus 로고
    • Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?
    • Nishizawa Y., Shoji T., Ishimura E., Inaba M., and Morii H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia?. Am J Kidney Dis 38 (2001) S4-S7
    • (2001) Am J Kidney Dis , vol.38
    • Nishizawa, Y.1    Shoji, T.2    Ishimura, E.3    Inaba, M.4    Morii, H.5
  • 11
    • 1642540483 scopus 로고    scopus 로고
    • Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition
    • Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 (2004) 451-459
    • (2004) JAMA , vol.291 , pp. 451-459
    • Liu, Y.1    Coresh, J.2    Eustace, J.A.3
  • 12
    • 33144484038 scopus 로고    scopus 로고
    • Mechanisms of dyslipidemia of chronic renal failure
    • Vaziri N.D., and Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 10 (2006) 1-7
    • (2006) Hemodial Int , vol.10 , pp. 1-7
    • Vaziri, N.D.1    Moradi, H.2
  • 13
    • 0025755287 scopus 로고
    • Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis
    • Attman P.O., and Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57 (1991) 401-410
    • (1991) Nephron , vol.57 , pp. 401-410
    • Attman, P.O.1    Alaupovic, P.2
  • 14
    • 0034816578 scopus 로고    scopus 로고
    • Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease
    • Quaschning T., Krane V., Metzger T., and Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis 38 (2001) S14-S19
    • (2001) Am J Kidney Dis , vol.38
    • Quaschning, T.1    Krane, V.2    Metzger, T.3    Wanner, C.4
  • 15
    • 0033016107 scopus 로고    scopus 로고
    • Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure
    • Vaziri N.D., Deng G., and Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14 (1999) 1462-1466
    • (1999) Nephrol Dial Transplant , vol.14 , pp. 1462-1466
    • Vaziri, N.D.1    Deng, G.2    Liang, K.3
  • 16
    • 0017275662 scopus 로고
    • Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man
    • Bagdade J., Casaretto A., and Albers J. Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med 87 (1976) 38-48
    • (1976) J Lab Clin Med , vol.87 , pp. 38-48
    • Bagdade, J.1    Casaretto, A.2    Albers, J.3
  • 17
    • 0036147221 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
    • Seliger S.L., Weiss N.S., Gillen D.L., et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61 (2002) 297-304
    • (2002) Kidney Int , vol.61 , pp. 297-304
    • Seliger, S.L.1    Weiss, N.S.2    Gillen, D.L.3
  • 18
    • 5644283332 scopus 로고    scopus 로고
    • Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients
    • Andreucci V.E., Fissell R.B., Bragg-Gresham J.L., et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 44 (2004) 61-67
    • (2004) Am J Kidney Dis , vol.44 , pp. 61-67
    • Andreucci, V.E.1    Fissell, R.B.2    Bragg-Gresham, J.L.3
  • 19
    • 22344458137 scopus 로고    scopus 로고
    • Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
    • Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
    • (2005) N Engl J Med , vol.353 , pp. 238-248
    • Wanner, C.1    Krane, V.2    Marz, W.3
  • 20
    • 34250640802 scopus 로고    scopus 로고
    • N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial
    • Svensson M., Schmidt E.B., Jorgensen K.A., and Christensen J.H. N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 1 (2006) 780-786
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 780-786
    • Svensson, M.1    Schmidt, E.B.2    Jorgensen, K.A.3    Christensen, J.H.4
  • 21
    • 0037407559 scopus 로고    scopus 로고
    • Why do we need a statin trial in hemodialysis patients?
    • Fellstrom B.C., Holdaas H., and Jardine A.G. Why do we need a statin trial in hemodialysis patients?. Kidney Int 63 Suppl (2003) S204-S206
    • (2003) Kidney Int , vol.63 , Issue.SUPPL
    • Fellstrom, B.C.1    Holdaas, H.2    Jardine, A.G.3
  • 22
    • 0037407617 scopus 로고    scopus 로고
    • Study of Heart and Renal Protection (SHARP)
    • Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 63 Suppl (2003) S207-S210
    • (2003) Kidney Int , vol.63 , Issue.SUPPL
    • Baigent, C.1    Landry, M.2
  • 23
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: a randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
    • (2002) Lancet , vol.360 , pp. 7-22
  • 24
    • 0037458229 scopus 로고    scopus 로고
    • Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency
    • Tonelli M., Moye L., Sacks F.M., Kiberd B., and Curhan G. Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
    • (2003) Ann Intern Med , vol.138 , pp. 98-104
    • Tonelli, M.1    Moye, L.2    Sacks, F.M.3    Kiberd, B.4    Curhan, G.5
  • 25
    • 8144224441 scopus 로고    scopus 로고
    • Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
    • Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
    • (2004) Circulation , vol.110 , pp. 2809-2816
    • Asselbergs, F.W.1    Diercks, G.F.2    Hillege, H.L.3
  • 26
    • 10744229858 scopus 로고    scopus 로고
    • Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    • Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
    • (2003) Lancet , vol.361 , pp. 2024-2031
    • Holdaas, H.1    Fellstrom, B.2    Jardine, A.G.3
  • 27
    • 2942592399 scopus 로고    scopus 로고
    • fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study
    • Jardine A.G., Holdaas H., Fellstrom B., et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant 4 (2004) 988-995
    • (2004) Am J Transplant , vol.4 , pp. 988-995
    • Jardine, A.G.1    Holdaas, H.2    Fellstrom, B.3
  • 28
    • 4344560351 scopus 로고    scopus 로고
    • Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficienc
    • Veterans' Affairs High-Density Lipoprotein Intervention Trial Investigators
    • Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C., and Veterans' Affairs High-Density Lipoprotein Intervention Trial Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficienc. Kidney Int 66 (2004) 1123-1130
    • (2004) Kidney Int , vol.66 , pp. 1123-1130
    • Tonelli, M.1    Collins, D.2    Robins, S.3    Bloomfield, H.4    Curhan, G.C.5
  • 29
    • 0037379751 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease
    • K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis 41 Suppl 3 (2003) S1-S237
    • (2003) Am J Kidney Dis , vol.41 , Issue.SUPPL. 3
  • 30
    • 20044372379 scopus 로고    scopus 로고
    • Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
    • Corsini A., and Holdass H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail 27 (2005) 259-273
    • (2005) Ren Fail , vol.27 , pp. 259-273
    • Corsini, A.1    Holdass, H.2
  • 31
    • 0028200059 scopus 로고
    • Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase
    • Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Am J Cardiol 73 (1994) 3D-11D
    • (1994) Am J Cardiol , vol.73
    • Blum, C.B.1
  • 32
    • 0025252565 scopus 로고
    • Proteinuria as complication of simvastatin treatment
    • Deslypere J.P., Delanghe J., and Vermeulen A. Proteinuria as complication of simvastatin treatment. Lancet 336 (1990) 1453
    • (1990) Lancet , vol.336 , pp. 1453
    • Deslypere, J.P.1    Delanghe, J.2    Vermeulen, A.3
  • 33
    • 22144442778 scopus 로고    scopus 로고
    • Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease
    • Tonelli M., Isles C., Craven T., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
    • (2005) Circulation , vol.112 , pp. 171-178
    • Tonelli, M.1    Isles, C.2    Craven, T.3
  • 34
    • 33745836406 scopus 로고    scopus 로고
    • Statins for improving renal outcomes: a meta-analysis
    • Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
    • (2006) J Am Soc Nephrol , vol.17 , pp. 2006-2016
    • Sandhu, S.1    Wiebe, N.2    Fried, L.F.3    Tonelli, M.4
  • 35
    • 32844458440 scopus 로고    scopus 로고
    • Effects of statins on renal function
    • Agarwal R. Effects of statins on renal function. Am J Cardiol 97 (2006) 748-755
    • (2006) Am J Cardiol , vol.97 , pp. 748-755
    • Agarwal, R.1
  • 36
    • 0031801034 scopus 로고    scopus 로고
    • In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation
    • Abbate M., Zoja C., Corna D., Capitanio M., Bertani T., and Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9 (1998) 1213-1224
    • (1998) J Am Soc Nephrol , vol.9 , pp. 1213-1224
    • Abbate, M.1    Zoja, C.2    Corna, D.3    Capitanio, M.4    Bertani, T.5    Remuzzi, G.6
  • 37
    • 0023508823 scopus 로고
    • The effect of renal function on the pharmacokinetics of gemfibrozil
    • Evans J.R., Forland S.C., and Cutler R.E. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 27 (1987) 994-1000
    • (1987) J Clin Pharmacol , vol.27 , pp. 994-1000
    • Evans, J.R.1    Forland, S.C.2    Cutler, R.E.3
  • 38
    • 0023634450 scopus 로고
    • Pharmacology of fenofibrate
    • Chapman M.J. Pharmacology of fenofibrate. Am J Med 83 (1987) 21-25
    • (1987) Am J Med , vol.83 , pp. 21-25
    • Chapman, M.J.1
  • 41
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
    • [see comment]
    • Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. [see comment]. Lancet 366 (2005) 1849-1861
    • (2005) Lancet , vol.366 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 42
    • 0032617597 scopus 로고    scopus 로고
    • Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency
    • Hottelart C., el Esper N., Achard J.M., Pruna A., and Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20 (1999) 41-44
    • (1999) Nephrologie , vol.20 , pp. 41-44
    • Hottelart, C.1    el Esper, N.2    Achard, J.M.3    Pruna, A.4    Fournier, A.5
  • 43
    • 0025348840 scopus 로고
    • Gemfibrozil absorption and elimination in kidney and liver disease
    • Knauf H., Kolle E.U., and Mutschler E. Gemfibrozil absorption and elimination in kidney and liver disease. Klin Wochenschr 68 (1990) 692-698
    • (1990) Klin Wochenschr , vol.68 , pp. 692-698
    • Knauf, H.1    Kolle, E.U.2    Mutschler, E.3
  • 44
    • 2342487350 scopus 로고    scopus 로고
    • The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels
    • Dierkes J., Westphal S., and Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 3 (2004) 101-111
    • (2004) Expert Opin Drug Saf , vol.3 , pp. 101-111
    • Dierkes, J.1    Westphal, S.2    Luley, C.3
  • 45
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • Anonymous
    • Anonymous. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
    • (1975) JAMA , vol.231 , pp. 360-381
  • 46
    • 0035822253 scopus 로고    scopus 로고
    • Effects of fenofibrate and gemfibrozil on plasma homocysteine
    • Westphal S., Dierkes J., and Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358 (2001) 39-40
    • (2001) Lancet , vol.358 , pp. 39-40
    • Westphal, S.1    Dierkes, J.2    Luley, C.3
  • 47
    • 33645800801 scopus 로고    scopus 로고
    • Fibrates in combination with statins in the management of dyslipidemia
    • Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens 8 (2006) 35-41
    • (2006) J Clin Hypertens , vol.8 , pp. 35-41
    • Jacobson, T.A.1    Zimmerman, F.H.2
  • 48
    • 33947124605 scopus 로고    scopus 로고
    • Safety considerations with gastrointestinally active lipid-lowering drugs
    • Jacobson T.A., Armani A., McKenney J.M., and Guyton J.R. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 99 (2007) 47C-55C
    • (2007) Am J Cardiol , vol.99
    • Jacobson, T.A.1    Armani, A.2    McKenney, J.M.3    Guyton, J.R.4
  • 49
    • 22244440549 scopus 로고    scopus 로고
    • Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients
    • Yamada K., Fujimoto S., Tokura T., et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 27 (2005) 361-365
    • (2005) Ren Fail , vol.27 , pp. 361-365
    • Yamada, K.1    Fujimoto, S.2    Tokura, T.3
  • 50
    • 32844473141 scopus 로고    scopus 로고
    • The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
    • Landray M., Baigent C., Leaper C., et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 (2006) 385-395
    • (2006) Am J Kidney Dis , vol.47 , pp. 385-395
    • Landray, M.1    Baigent, C.2    Leaper, C.3
  • 51
    • 0037126526 scopus 로고    scopus 로고
    • Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program Expert Panel on Detection
    • National Cholesterol Education Program Expert Panel on Detection. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 52
    • 20444399162 scopus 로고    scopus 로고
    • Nonfasting nonhigh-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients
    • Desmeules S., Arcand-Bosse J.F., Bergeron J., Douville P., and Agharazii M. Nonfasting nonhigh-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 45 (2005) 1067-1072
    • (2005) Am J Kidney Dis , vol.45 , pp. 1067-1072
    • Desmeules, S.1    Arcand-Bosse, J.F.2    Bergeron, J.3    Douville, P.4    Agharazii, M.5
  • 53
    • 33947113384 scopus 로고    scopus 로고
    • Safety considerations with omega-3 fatty acid therapy
    • Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99 (2007) 35C-43C
    • (2007) Am J Cardiol , vol.99
    • Bays, H.E.1
  • 54
    • 33747129220 scopus 로고    scopus 로고
    • Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids
    • Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 98 (2006) 71i-76i
    • (2006) Am J Cardiol , vol.98
    • Bays, H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.